Anavex Life Sciences Corp.
Σύμβολο: AVXL
NASDAQ
3.85
USDΤιμή αγοράς σήμερα
-7.3224
Λόγος P/E
-2.2699
Δείκτης PEG
311.23M
MRK Cap
- 0.00%
DIV Απόδοση
Anavex Life Sciences Corp. (AVXL) Οικονομικές καταστάσεις
Ισολογισμός
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 603.07 | 151 | 149.2 | 152.1 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 13.16 | 2.7 | 3.2 | 9.1 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 3.22 | 0.7 | 0.4 | 0.4 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 619.45 | 154.4 | 152.7 | 161.6 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 3.36 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 3.36 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-assets | 8713.08 | 3.4 | 3546.7 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 619.45 | 154.4 | 152.7 | 161.6 | ||||||||||||||||||||
balance-sheet.row.account-payables | 19.05 | 4.3 | 3.8 | 4.7 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 27.39 | 7.3 | 5.9 | 5.6 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 12823.08 | 7.3 | 4.3 | 5.6 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | -12823.08 | -7.3 | -4.3 | -5.6 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-liab | 50.11 | 12.5 | 10.2 | 10.8 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0.33 | 0.1 | 0.1 | 0.1 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | -1149.33 | -293.1 | -245.6 | -197.6 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1718.35 | 434.8 | 388 | 348.3 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 569.35 | 141.9 | 142.5 | 150.8 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 619.45 | 154.4 | 152.7 | 161.6 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 569.35 | 141.9 | 142.5 | 150.8 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 619.45 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.net-debt | -603.07 | -151 | -149.2 | -152.1 |
Κατάσταση ταμειακών ροών
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -43.16 | -47.5 | -48 | -37.9 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 13.31 | 16.4 | 18.4 | 8.2 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | -0.31 | 2.5 | 5.4 | -0.7 | ||||||||||||||||||||
cash-flows.row.account-receivables | 0.55 | 0.5 | 5.9 | -4.3 | ||||||||||||||||||||
cash-flows.row.inventory | -1.53 | -0.5 | -5.9 | 4.3 | ||||||||||||||||||||
cash-flows.row.account-payables | -1 | 0.5 | -0.9 | 0.8 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 1.67 | 2 | 6.3 | -1.5 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 0.84 | 0.8 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -29.31 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 27.93 | 27.9 | 21 | 153.2 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 1.52 | 1.8 | 0.3 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 29.45 | 29.7 | 21.3 | 153.2 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | 0.14 | 1.9 | -2.9 | 122.9 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 603.07 | 151 | 149.2 | 152.1 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 602.93 | 149.2 | 152.1 | 29.2 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | -29.31 | -27.8 | -24.2 | -30.4 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | -29.31 | -27.8 | -24.2 | -30.4 |
Σειρά κατάστασης λογαριασμού αποτελεσμάτων
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 40.33 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 11.33 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 2.58 | 2.7 | 3.3 | -0.1 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 51.67 | 55.8 | 51 | 41.9 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 51.67 | 55.8 | 51 | 41.9 | ||||||||||||||||||||
income-statement-row.row.interest-income | 7.26 | 6.5 | 0.9 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | -1.13 | 1 | 0.9 | 0 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 2.83 | 2.7 | 6.8 | 4.3 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 2.58 | 2.7 | 3.3 | -0.1 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 2.83 | 2.7 | 6.8 | 4.3 | ||||||||||||||||||||
income-statement-row.row.interest-expense | -1.13 | 1 | 0.9 | 0 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 2.23 | 0 | 4.3 | 0.2 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | -46.68 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | -48.91 | -47.5 | -54.4 | -41.9 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | -43.04 | -47.5 | -47.6 | -37.6 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0.11 | 0 | 0.4 | 0.3 | ||||||||||||||||||||
income-statement-row.row.net-income | -43.16 | -47.5 | -48 | -37.9 |
Συχνές ερωτήσεις
Ποιο είναι το Anavex Life Sciences Corp. (AVXL) το σύνολο του ενεργητικού?
Anavex Life Sciences Corp. (AVXL) το συνολικό ενεργητικό είναι 154386000.000.
Ποια είναι τα ετήσια έσοδα της επιχείρησης?
Τα ετήσια έσοδα είναι N/A.
Ποιο είναι το περιθώριο κέρδους της επιχείρησης?
Το περιθώριο κέρδους της επιχείρησης είναι 0.000.
Ποια είναι η ελεύθερη ταμειακή ροή της επιχείρησης?
Η ελεύθερη ταμειακή ροή είναι -0.357.
Ποιο είναι το καθαρό περιθώριο κέρδους της επιχείρησης?
Το καθαρό περιθώριο κέρδους είναι 0.000.
Ποια είναι τα συνολικά έσοδα της επιχείρησης?
Τα συνολικά έσοδα είναι 0.000.
Ποια είναι η Anavex Life Sciences Corp. (AVXL) καθαρό κέρδος (καθαρό εισόδημα)?
Το καθαρό κέρδος (καθαρό εισόδημα) είναι -47491000.000.
Ποιο είναι το συνολικό χρέος της επιχείρησης?
Το συνολικό χρέος είναι 0.000.
Ποιος είναι ο αριθμός των λειτουργικών εξόδων?
Τα λειτουργικά έξοδα είναι 55756000.000.
Ποιος είναι ο αριθμός των ταμειακών διαθεσίμων της εταιρείας?
Τα ταμειακά διαθέσιμα της επιχείρησης είναι 143765000.000.